Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INV-9956 in Advanced Metastatic Castration Resistant Prostate Cancer
NCT06609005Phase 2Recruiting
- Sponsor
- Ionova Life Science
- Start
- Jan 2025
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of INV-9956 in castration-resistant prostate cancer (CRPC) (8 arms), sponsored by Ionova Life Science. Primary endpoints: Maximum Tolerated Dose at 28 days, Recommended Dose Range at 12 months and 2 more. Started Jan 2025; status: recruiting.
02
Drugs
INV-9956
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT06609005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06609005.